MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle. The combined company will focus on the MedAvail business and its shares will trade on the Nasdaq Capital Market under the new trading symbol “MDVL.” The current MYOS RENS muscle health business will be spun off as a private unaffiliated company.
Cigna Ventures | Health Care Venture Capital
Footer
By contacting The Cigna Group Ventures through this website, you agree and acknowledge that information you submit will not be considered or treated as confidential or proprietary unless and until a separate agreement is signed and that The Cigna Group Ventures and its affiliates are under no obligation to review your submission or to enter into any agreement, investment or transaction associated with the submission. In no event will The Cigna Group Ventures or any of its affiliates be limited in, or restricted from, the pursuit of any opportunities, either alone or with third parties.
The information contained herein does not constitute a distribution, an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction in which such distribution or offer is not authorized. In particular, the information herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States (U.S.) or for the benefit of any U.S. person (being residents of the United States or partnerships or corporations organized under the laws of the United States), nor in any other country.